Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $34

Benzinga · 23h ago
Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $39 to $34.